Volker Morath

Title: Volker Morath: Innovator in Biopharmaceuticals

Introduction

Volker Morath is a notable inventor based in Munich, Germany. He has made significant contributions to the field of biopharmaceuticals, specifically in the development of binding proteins that target human proteins for therapeutic applications. His innovative work is encapsulated in his patent, which focuses on the specificity and affinity of binding proteins.

Latest Patents

Morath holds one patent titled "High affinity anticalins directed against human CD98hc." This invention pertains to a cluster of differentiation 98 heavy chain (CD98hc)-specific binding protein. The protein, derived from lipocalin 2 (Lcn2), demonstrates a binding affinity to CD98hc with a Koff value of 200 nM or lower. This remarkable characteristic makes it a potential candidate for therapeutic applications targeting related diseases.

Career Highlights

Currently, Volker Morath works at the Technische Universität München, where he engages in transformative research that bridges the gap between academia and practical applications in the pharmaceutical industry. His rigorous research and inventive mindset have positioned him as a key player in his field.

Collaborations

Throughout his career, Morath has collaborated with various individuals to enhance his research initiatives. One notable coworker is Friedrich-Christian Deuschle, with whom he has likely shared insights and expertise to further explore the potentials of their inventions in targeted therapies.

Conclusion

Volker Morath exemplifies the spirit of innovation in the field of biopharmaceuticals. Through his patent and ongoing research at the Technische Universität München, he continues to contribute to important advancements that could lead to new therapies and healthier futures. His dedication to invention and collaboration underscores the importance of teamwork in scientific advancements.